ANALYSIS OF INTRAHEPATIC MACROPHAGE PROFILES FOR PREDICTING RISK OF FIBROSIS DEVELOPMENT IN PATIENTS WITH DIFFERENT TYPES OF CHRONIC LIVER DISEASE
分析肝内巨噬细胞谱以预测不同类型慢性肝病患者纤维化发展的风险
基本信息
- 批准号:10355539
- 负责人:
- 金额:$ 54.77万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-04-01 至 2026-03-31
- 项目状态:未结题
- 来源:
- 关键词:AcidsAdvanced DevelopmentAlcoholsAnti-Inflammatory AgentsAntigensArchivesAutoimmune HepatitisBioinformaticsBiological MarkersBiological ModelsBiopsyBloodCCL2 geneCCR5 geneCellsChronic HepatitisCirrhosisClinicalClinical ResearchClinical TreatmentComplementDataData AnalysesDevelopmentDiagnosisDiscontinuous CapillaryDiseaseEconomic BurdenEndothelial CellsEtiologyExhibitsEyeFibrosisFormalinFutureGalectin 3GatekeepingGene ExpressionGenesHepaticHepatitis C virusHumanImageImmunotherapyIn SituIn VitroInflammatoryInjuryKupffer CellsLife Style ModificationLiverLiver FibrosisLiver diseasesLocationLongitudinal StudiesMalignant NeoplasmsMediator of activation proteinMolecularOutcomeParaffin EmbeddingPathogenicityPatientsPerisinusoidal SpacePhase II/III Clinical TrialPhenotypePopulationPredispositionPrimary carcinoma of the liver cellsPrior TherapyProcessProgressive DiseasePruritusRiskSlideTechniquesTechnologyTestingTherapeutic InterventionTimeTissue EmbeddingTissue StainsTissuesTransforming Growth Factor betaTumor Necrosis Factor-BetaVariantbiobankchronic liver diseaseclinical careclinical implementationcostcost efficientdesignfollow-uphealth economicsimprovedinnovationintrahepaticliver biopsyliver injurymacrophagemicroscopic imagingmouse modelnano-stringnon-alcoholic fatty liver diseasenon-compliancenonalcoholic steatohepatitispatient variabilitypersonalized medicineprognosticprospectiverecruitresponseside effectspectrographstandard of carestellate celltargeted treatmenttherapeutic candidatetherapeutic target
项目摘要
PROJECT SUMMARY/ABSTRACT
Cirrhosis and hepatocellular carcinoma are increasing health and economic burdens. Non-alcoholic fatty liver
disease (NAFLD/NASH), alcohol-associated liver disease (AALD), chronic hepatitis (CHC), and autoimmune
hepatitis (AIH) are common etiologies. Unfortunately, many patients do not adhere to recommended life style
modifications, thus, we need better techniques for predicting risk of fibrosis progression and personalizing
therapies prior to development of poor outcomes. Intrahepatic macrophages (Macs), liver sinusoidal endothelial
cells (LSECs), and stellate cells (HSCs) can greatly influence the composition of the hepatic microenvironment
and development of fibrosis. Therapies targeting these initiators of fibrosis are being investigated in phase II-III
clinical trials; however, the underlying hepatic microenvironment and patient variability in these cells and
expression of these targets is not being considered prior to treatment. We use cutting-edge spectral imaging
microscopy combined with NanoString technology to evaluate these cells and associated pro-fibrotic gene
expression profiles in the same patient's liver biopsy at the time of initial diagnosis. From our liver tissue biobank,
we identified 225 biopsies with different chronic liver diseases (NASH, AALD, CHC, and AIH) that were collected
at the time of diagnosis from patients that had adequate follow-up either with a repeat biopsy or by liver
replacement (for those that later developed cirrhosis). The majority showed no progression of hepatic fibrosis
over time (n = 150) while a portion rapidly developed cirrhosis (n = 75). We use the above platforms to assess
differences in these patients' hepatic microenvironments in their initial liver biopsies. We propose to test the
hypothesis that patients with definable pro-fibrotic variations in their hepatic microenvironment early in the course
of disease predicts their propensity to develop fibrosis. Preliminary data showed that initial liver biopsies from
patients with a predisposition to rapidly develop cirrhosis have increased profibrotic macrophages (e.g.,
Mac387+ and CD163+, respectively), enhanced cellular interactions of Mac-LSEC-HSCs, increased expression
of therapy-related targets (e.g., CCR2 and galectin 3) and increased pro-inflammatory/pro-fibrotic gene
expression profiles (e.g., CCL2, TNF, and TGF-beta). Imaging and molecular bioinformatics will be used for data
analyses. For Aim 1, we will use three panels to phenotype intrahepatic Macs and examine their interactions
with LSECs and HSCs, and will assess differences in expression of pro-fibrotic therapy-related targets. For Aim
2, we will analyze over 200 Mac-LSEC-HSC-related and pro-fibrotic genes in the other half of the biopsy from
Aim 1. The proposed approach will lay the groundwork for our long-term objective: personalization of targeted
therapies (e.g., cenicriviroc or obeticholic acid), similar to the manner in which the response to immunotherapy
is predicted by staining of tissue in patients with cancer. In this retrospective longitudinal study, we will determine
which platform (Spectral imaging-Aim1 vs. NanoString-Aim 2) is the most performant for determining potential
targets of fibrosis progression and most cost efficient for clinical implementation in the future.
项目总结/摘要
肝硬化和肝细胞癌正在增加健康和经济负担。非酒精性脂肪肝
疾病(NAFLD/NASH)、酒精相关性肝病(AALD)、慢性肝炎(CHC)和自身免疫性
肝炎(AIH)是常见病因。不幸的是,许多患者不坚持推荐的生活方式
因此,我们需要更好的技术来预测纤维化进展的风险,
在出现不良结果之前进行治疗。肝内巨噬细胞(Macs),肝窦内皮
细胞(LSEC)和星状细胞(HSC)可以极大地影响肝脏微环境的组成
和纤维化的发展。针对这些纤维化引发剂的治疗正在研究中,
然而,这些细胞中的潜在肝脏微环境和患者变异性,
在治疗前不考虑这些靶点的表达。我们使用最先进的光谱成像技术
显微镜结合NanoString技术来评估这些细胞和相关的促纤维化基因
在同一患者的肝活检中的表达谱在最初诊断时。从我们的肝脏组织生物库,
我们确定了225例不同慢性肝病(NASH、AALD、CHC和AIH)的活检标本,
在诊断时,来自通过重复活检或肝脏进行了充分随访的患者
替代(对于那些后来发展为肝硬化的人)。大多数显示肝纤维化无进展
随着时间的推移(n = 150),而一部分迅速发展为肝硬化(n = 75)。我们使用上述平台来评估
这些患者在其初始肝活检中的肝微环境的差异。我们建议测试
假设患者在病程早期肝脏微环境中存在可确定的促纤维化变化
疾病的发生率预测了他们发展纤维化的倾向。初步数据显示,
具有快速发展肝硬化倾向的患者具有增加的促纤维化巨噬细胞(例如,
Mac 387+和CD 163+),增强Mac-LSEC-HSC的细胞相互作用,增加表达
治疗相关的目标(例如,CCR 2和半乳糖凝集素3)和促炎/促纤维化基因增加
表达谱(例如,CCL 2、TNF和TGF-β)。成像和分子生物信息学将用于数据
分析。对于目标1,我们将使用三组表型肝内MAC并检查它们的相互作用
与LSEC和HSC,并将评估促纤维化治疗相关靶点的表达差异。为宗旨
2,我们将分析另一半活检组织中超过200个Mac-LSEC-HSC相关和促纤维化基因,
目标1。所提出的方法将为我们的长期目标奠定基础:
治疗(例如,赛尼克韦罗或奥贝胆酸),类似于对免疫疗法的应答的方式。
通过癌症患者的组织染色来预测。在这项回顾性纵向研究中,我们将确定
哪种平台(光谱成像-Aim 1与NanoString-Aim 2)在确定潜在风险方面性能最佳
纤维化进展的目标,并且对于未来的临床实施是最具成本效益的。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
HEATHER L STEVENSON其他文献
HEATHER L STEVENSON的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('HEATHER L STEVENSON', 18)}}的其他基金
ANALYSIS OF INTRAHEPATIC MACROPHAGE PROFILES FOR PREDICTING RISK OF FIBROSIS DEVELOPMENT IN PATIENTS WITH DIFFERENT TYPES OF CHRONIC LIVER DISEASE
分析肝内巨噬细胞谱以预测不同类型慢性肝病患者纤维化发展的风险
- 批准号:
10848068 - 财政年份:2021
- 资助金额:
$ 54.77万 - 项目类别:
ANALYSIS OF INTRAHEPATIC MACROPHAGE PROFILES FOR PREDICTING RISK OF FIBROSIS DEVELOPMENT IN PATIENTS WITH DIFFERENT TYPES OF CHRONIC LIVER DISEASE
分析肝内巨噬细胞谱以预测不同类型慢性肝病患者纤维化发展的风险
- 批准号:
10598475 - 财政年份:2021
- 资助金额:
$ 54.77万 - 项目类别:
ANALYSIS OF INTRAHEPATIC MACROPHAGE PROFILES FOR PREDICTING RISK OF FIBROSIS DEVELOPMENT IN PATIENTS WITH DIFFERENT TYPES OF CHRONIC LIVER DISEASE
分析肝内巨噬细胞谱以预测不同类型慢性肝病患者纤维化发展的风险
- 批准号:
10211976 - 财政年份:2021
- 资助金额:
$ 54.77万 - 项目类别:
相似海外基金
ADVANCED DEVELOPMENT OF LQ A LIPOSOME-BASED SAPONIN-CONTAINING ADJUVANT FOR USE IN PANSARBECOVIRUS VACCINES
用于 Pansarbecovirus 疫苗的 LQ A 脂质体含皂苷佐剂的先进开发
- 批准号:
10935820 - 财政年份:2023
- 资助金额:
$ 54.77万 - 项目类别:
ADVANCED DEVELOPMENT OF BBT-059 AS A RADIATION MEDICAL COUNTERMEASURE FOR DOSING UP TO 48H POST EXPOSURE"
BBT-059 的先进开发,作为辐射医学对策,可在暴露后 48 小时内进行给药”
- 批准号:
10932514 - 财政年份:2023
- 资助金额:
$ 54.77万 - 项目类别:
Advanced Development of a Combined Shigella-ETEC Vaccine
志贺氏菌-ETEC 联合疫苗的先进开发
- 批准号:
10704845 - 财政年份:2023
- 资助金额:
$ 54.77万 - 项目类别:
Advanced development of composite gene delivery and CAR engineering systems
复合基因递送和CAR工程系统的先进开发
- 批准号:
10709085 - 财政年份:2023
- 资助金额:
$ 54.77万 - 项目类别:
Advanced development and validation of an in vitro platform to phenotype brain metastatic tumor cells using artificial intelligence
使用人工智能对脑转移肿瘤细胞进行表型分析的体外平台的高级开发和验证
- 批准号:
10409385 - 财政年份:2022
- 资助金额:
$ 54.77万 - 项目类别:
ADVANCED DEVELOPMENT OF A VACCINE FOR PANDEMIC AND PRE-EMERGENT CORONAVIRUSES
针对大流行和突发冠状病毒的疫苗的高级开发
- 批准号:
10710595 - 财政年份:2022
- 资助金额:
$ 54.77万 - 项目类别:
Advanced development and validation of an in vitro platform to phenotype brain metastatic tumor cells using artificial intelligence
使用人工智能对脑转移肿瘤细胞进行表型分析的体外平台的高级开发和验证
- 批准号:
10630975 - 财政年份:2022
- 资助金额:
$ 54.77万 - 项目类别:
ADVANCED DEVELOPMENT OF A VACCINE CANDIDATE FOR STAPHYLOCOCCUS AUREUS INFECTION
金黄色葡萄球菌感染候选疫苗的高级开发
- 批准号:
10710588 - 财政年份:2022
- 资助金额:
$ 54.77万 - 项目类别:
ADVANCED DEVELOPMENT OF A VACCINE FOR PANDEMIC AND PRE-EMERGENT CORONAVIRUSES
针对大流行和突发冠状病毒的疫苗的高级开发
- 批准号:
10788051 - 财政年份:2022
- 资助金额:
$ 54.77万 - 项目类别: